Key Metrics of Bharat Rasayan Limited
About Bharat Rasayan Limited
Company details
- Registered office
- 1501 Vikram Tower Rajendra Place, New Delhi, In-dl, 110008
- Listed
- NSE: BHARATRAS · ₹936.80
Company summary
Entity details
Compliance
Industry classification
Financials, ratios and risk analysis
Revenue, EBITDA, net profit, net worth, debt and assets for every filing year, 15+ ratios, the financial health score, shareholding, charges and peer comparison are part of the premium plan.
Sign in to continue See plans & pricingFiling compliance
Due dates follow the Companies Act: AGM within six months of the year end, AOC-4 within 30 days and MGT-7 within 60 days of the AGM. A filing made but not yet uploaded here shows as pending.
Vendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Credit ratings
Rating history
Rating actions
| Date | Agency | Action | Long term | Short term | Outlook | Rated amount | Rationale |
|---|---|---|---|---|---|---|---|
| 18 Dec 2025 | CARE | Other | — | — | — | — | View |
| 09 Dec 2024 | CARE | Reaffirmed | AA- | A1+ | Stable | ₹250 Cr | View |
| 04 Apr 2024 | CARE | Reaffirmed | AA- | A1+ | Stable | ₹250 Cr | View |
| 27 Dec 2023 | CARE | Reaffirmed | AA- | A1+ | Stable | ₹350 Cr | View |
| 03 Jan 2023 | CARE | Reaffirmed | AA- | A1+ | Stable | ₹700 Cr | View |
| 25 May 2022 | CARE | Other | — | — | — | — | View |
| 23 Dec 2021 | CARE | Reaffirmed | AA- | A1+ | Stable | ₹250 Cr | View |
| 20 Dec 2021 | CARE | Reaffirmed | AA- | A1+ | Stable | ₹500 Cr | View |
| 30 Dec 2020 | CARE | Reaffirmed | AA- | A1+ | Stable | ₹400 Cr | View |
| 22 Dec 2020 | CARE | Other | — | — | — | ₹50.0 Cr | View |
| 27 Dec 2019 | CARE | Reaffirmed | AA- | A1+ | Stable | ₹250 Cr | View |
Credit strengths (CARE, Dec 2025)
+ Integrated operations offering diversified product mix
BRL has a leading market position in many technical and intermediate products, including Lambda Cyhalothrin Technical, Meta phenoxy Benzaldehyde, Metribuzine Technical, Thiamethoxam (Insecticides) and Fipronil (Insecticides) among others. Though 1Complete definition of ratings assigned are available at www.careratings.com and other CARE Ratings Limited’s publications. 1 CARE Ratings Ltd. Press Release there is a slight product concentration risk, as BRL’s top three products accounts for ~25% of
+ Long-standing relationship with reputed customer base
The company supplies its products in local and overseas locations and has a long-standing relationship with reputed customers, including NISSEI Corporation, Syngenta Crop, Sumitomo Chemical Company Limited, Shanghai Agro tree Chemical Corporation Limited, and Rallis India Limited among others. BRL has 489 domestic registrations and 123 international registrations and has been exporting its products to over 24 countries across the globe. However, BRL is exposed to moderate client concentration ri
+ BRL also has long-standing associations with several reputed Japanese players and holds a 30:70 JV with Nissan Chemical
Corporation (NCC), which commenced commercial production in March 2023. The JV reported a total income of ₹373 crore in FY25 and ₹134 crore in H1FY26, with a profit after taxation (PAT) margin of 14% in FY25 and -6% in H1FY26. The negative PAT in H1FY26 was primarily considering a notional foreign exchange loss booked in the profit and loss account. Recovery in domestic demand in FY25 and strong financial risk profile
+ Recovery in domestic demand in FY25 and strong financial risk profile
In FY25, domestic demand recovered following above-average rainfall in key crop areas, supporting a rebound in operational performance after reporting a year-over-year degrowth due to weak industry-wide demand and a decline in prices driven by EL Nino and destocking by Chinese counterparts. In FY25, the company reported TOI of ₹1,183 crore (PY: ₹1,059.26 crore), PBILDT of ₹185.04 crore (₹ 132.32 crore), and a margin of 15.6% (PY:12.5%). The recovery continued into H1FY26, with TOI of ₹663.4
+ Experienced and resourceful promoters with long track record of operations in pesticides industry
BRL is part of the Bharat group; one of the leading manufacturers of technical grade pesticides in India and has been engaged in manufacturing and selling pesticides for over four decades. The company’s promoters have also extended support in terms of financial assistant to working capital requirements of the company in the past. The group’s directors are supported by a team of professionals with rich experience in varied spheres of business.
Credit challenges
− Profitability and sales susceptible to monsoon and climatic conditions
The pesticide/crop protection industry derives its sales from the agriculture sector , which highly depends on monsoons and incidence of fungal/pest attack on crops. Major fluctuations in total rainfall and its distribution affect the crop and overa ll productivity and has a direct correlation with sales and profitability of the pesticides i ndustry. However, the risk is partially mitigated through the company’s wide geographical presence covering over 21 states in India and over 24 countries, w
− Exposure towards highly regulated and competitive agrochemical industry
The pesticides industry is marked by heavy fragmentation with the absence of key player having sizeable market share. Intense competition leads to competitive pricing and lower margins. Traditionally, Indian players concentrated on marketing generic and off-patent products with little expenditure on research and development (R&D), while MNCs focused on developing patented molecules. BRL is supported by a dedicated R&D team that consistently works on developing innovative new products, ensuring
− Exposure towards foreign currency fluctuation risk
The Bharat Group is exposed to foreign currency fluctuation risk, as BRL’s export sales constitute ~around 26% of the company’s total sales in FY25 (PY: ~36.13%). BRL is also importing raw materials for manufacturing technical grade pesticides, as ~50% of the total purchases is imported, mainly from China (85% of total imports), Japan (12-14%) and balance from other countries. Thus, foreign exchange fluctuation risk is reduced, partially considering natural hedge available in the form of export
− Working capital intensive operations due to high inventory requirements and longer collection period
The pesticide industry requires high working capital investment due to high inventory holding and longer credit period on sales due to the commoditised products and seasonality factor. Average inventory holding remains at elevated level and stood ~101 days in FY25, though slightly reduced from 116 days in FY24. Providing extended credit is necessary to stimulate demand as farmers are left with little surplus money for purchasing pesticides after having invested in seeds, and fertilisers, among o
Could lead to an upgrade
Factors that could individually or collectively lead to positive rating action/upgrade: • The company’s ability to enhance its scale of operations over ₹1,400 crore and PBILDT margin over 15% on a sustained basis.
Could lead to a downgrade
Factors that could individually or collectively lead to negative rating action/downgrade: • Significant increase in the working capital cycle on a sustained basis impacting BRL’s
Agency-reported financials (CARE, 18 Dec 2025)
| Metric | March 31, 2024 | March 31, 2025 | H1FY26 |
|---|---|---|---|
| Total operating income | ₹1,059 Cr | ₹1,183 Cr | ₹663 Cr |
| PBILDT | ₹132 Cr | ₹185 Cr | ₹102 Cr |
| PAT | ₹95.51 Cr | ₹141 Cr | ₹67.34 Cr |
| Overall gearing (times) | 0.08× | 0.07× | — |
| Interest coverage (times) | 44.68× | 38.19× | 45.11× |
| Revenue growth (YoY) | — | 11.7% | — |
| EBITDA margin | 12.5% | 15.6% | 15.4% |
| Implied interest cost (EBITDA ÷ coverage) | ₹2.96 Cr | ₹4.85 Cr | ₹2.27 Cr |
| PAT margin | 9.0% | 11.9% | 10.2% |
Borrowings & rated debt
Rated limits over time
Facility mix
Rated facilities
| Facility | Type | Previous | Current | Change | Rating | Action | Agency |
|---|---|---|---|---|---|---|---|
| Long-term bank facilities | Working capital & bank lines | — | ₹149 Cr | — | AA- (Stable) | Reaffirmed | CARE |
| Short-term bank facilities | Working capital & bank lines | — | ₹101 Cr | — | A1+ | Reaffirmed | CARE |
CARE ratings on record (checked 22 Oct 2026)
| Instrument | Amount | Rating |
|---|---|---|
| BG/LC | ₹101 Cr | CARE A1+ |
| Cash Credit | ₹149 Cr | CARE AA-; Stable |
| Commercial Paper (Carved out) | — | Withdrawn |
| Commercial Paper (Standalone) | — | Withdrawn |
| Term Loan | — | Withdrawn |
Lenders
| Fund-based - LT | Cash Credit | HDFC Bank Ltd. |
| Fund-based - LT | Cash Credit | ICICI Bank Ltd. |
| Fund-based - LT | Cash Credit | State Bank of India |
| Non-fund-based - ST | BG/LC | HDFC Bank Ltd. |
| Non-fund-based - ST | BG/LC | ICICI Bank Ltd. |
| Non-fund-based - ST | BG/LC | State Bank of India |
Credit assessment · Manufacturing
Rating Methodology – Manufacturing Companies (Mar 2025) · Standalone accounts · FY 2025-26
Ratios, pillar scores and the indicative rating are part of Premium.
Rating status
| Default | No default on record |
| Issuer cooperation | Cooperating |
| Credit enhancement | None – standalone rating |
| Next action stable or better (model) | 73% |
| Information on file | 78% · missing: Capex / investment plans, Auditor details |
Indicative assessment from public data using the published methodology factors; not a credit rating.
Borrowing & funding lifecycle
- Credit outlook model: 57% chance the next rating action is stable or better
- Interest coverage 45.11×
Rated limits by facility
Timeline
From the report
The company has a strong liquidity position, reflected in total liquidity of ₹285.51 crore, comprising ₹55 crore in cash and ₹230 crore in mutual funds, against a total debt of ₹85.22 crore as on March 31, 2025.
From the report
The company’s liquidity stood at ₹285.51 crore as on March 31, 2025 (against total debt of ₹85.22 crore) comprising of ₹230.1 crore investments in mutual funds and ₹55.41 crore in cash and cash equivalents, which increased from total liquidity of ₹124.64 crore as on March 31, 2024, owing to healthy cash generation and faster turnaround on y-o-y basis as operating cycle reduced to 189 days in FY25 from 212 days in FY24.
From the report
The company’s cash and cash equivalents stood at ₹32.43 crore as on March 31, 2024, which increased to ₹40.56 crore as on September 30, 2024.
From the report
Its unutilised fund-based bank lines are more-than-adequate to meet its incremental working capital needs over the next one year as the average utilisation for the trailing 12 months ending October 2024 stood at only 1.58%.
From the report
Stable Reaffirmed Short-term bank facilities 101.00 CARE A1+ Reaffirmed Commercial paper (standalone) - - Withdrawn Commercial paper (carved out)* - - Withdrawn Details of instruments/facilities in Annexure-1. *Carved out of sanctioned working capital limits of the company Rationale and key rating drivers The reaffirmation in the ratings assigned to the bank facilities of Bharat Rasayan Limited (BRL) continues to derive strengthfrom the long track record of the promoters in the pesticides industry and group’s integrated operations marked by presence across the entire value chain of the pestici
From the report
CARE Ratings Limited (CARE) has withdrawn the outstanding rating of CARE A1+ assigned to the commercial paper (CP) issue of BRL with immediate effect, as the company has not availed the aforementioned CP instruments rated by CARE and there is no amount outstanding under the said instruments as on date.
From the report
Liquidity: Strong The liquidity is marked by healthy expected cash accruals of close to ₹70 crore in FY24 against zero debt repayment obligations and liquid investments to the tune of ₹91.54 crore as on March 28, 2024, largely held in the form of SBI mutual funds.
From the report
Stable Reaffirmed Short-term bank facilities 101.00 CARE A1+ Reaffirmed Commercial paper 50.00 CARE A1+ Reaffirmed Commercial paper (Carved out)* 50.00 CARE A1+ Reaffirmed Details of instruments/facilities in Annexure-1. *Carved out of sanctioned working capital limits of the company Rationale and key rating drivers The reaffirmation in the ratings assigned to the bank facilities of Bharat Rasayan Limited (BRL) continues to derive strength from the long track record of the promoters in the pesticides industry and group’s integrated operations marked by presence across the entire value chain of
From the report
Liquidity: Strong The liquidity is marked by healthy expected cash accruals of close to ₹70 crore in FY24 against zero debt repayment obligations and liquid investments to the tune of ₹110.28 crore as on September 30, 2023, largely held in the form of SBI mutual funds (SBI overnight debt fund; no lock-in period).
From the report
Its unutilised fund-based bank lines of more than ₹79 crore as on September 30, 2023 are more-than-adequate to meet its incremental working capital needs over the next one year (average utilisation remained low around 18-20% for trailing 12 months ending with September 30, 2023, against sanctioned limit of ₹149.00 crore).
From the report
Its unutilised fund-based bank lines of more than ₹79 crore as on September 30, 2023 are more-than-adequate to meet its incremental working capital needs over the next one year (average utilisation remained low around 18-20% for trailing 12 months ending with September 30, 2023, against sanctioned limit of ₹149.00 crore).
Lender names, bank charges and audited borrowings are part of Premium.
Built from MCA charges, ICRA/CARE rating reports and audited accounts. The borrowing view is an estimate, not a lender's credit decision.
Registered office and contact
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.
